Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
2(18%)
Results Posted
33%(3 trials)

Phase Distribution

Ph phase_2
3
27%
Ph phase_1
6
55%
Ph phase_3
2
18%

Phase Distribution

6

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(9)

Detailed Status

Completed9
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (54.5%)
Phase 23 (27.3%)
Phase 32 (18.2%)

Trials by Status

active_not_recruiting19%
recruiting19%
completed982%

Recent Activity

2 active trials
Showing 5 of 11
active_not_recruitingphase_2

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198
completedphase_1

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

NCT03674814
recruitingphase_2

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
completedphase_2

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03776812
completedphase_3

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

NCT04308590
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03604198Phase 2

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Active Not Recruiting
NCT03674814Phase 1

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Completed
NCT05726292Phase 2

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Recruiting
NCT03776812Phase 2

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed
NCT04308590Phase 3

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Completed
NCT03697109Phase 3

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Completed
NCT04373265Phase 1

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Completed
NCT06094725Phase 1

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Completed
NCT05347979Phase 1

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Completed
NCT04795479Phase 1

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Completed
NCT03457597Phase 1

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11